|
There is no doubt an unmet medical need for new oncology medications with a favourable balance between benefit and harm. In the last few decades, there have been substantial improvements of therapy in some other therapeutic areas, while there have been relatively few breakthroughs in the management of cancer patients. Thus, there is a need for new cancer medications with unique mechanisms of actions. |
 |
 |
 |
 |
 |
 |
 |
|
Using unique screening methods Vivolux scientists have identified substances and related analogues with remarkable effects on human cancer cells in vitro and on tumour growth in animals. The substances are not chemically related to any of the marketed oncology medications.
|
Drug Activity Profiling System (DAPS), a unique screening method using primary cultures of patient tumor cells
3-D multicellular spheroids, a screening method that represents a conceptually new strategy for anticancer drug discovery. Spheroids of human cancer cells are exposed to a panel of compounds and induction of apoptosis and loss of cell viability is determined. |
Dhar S et al. Anticancer drug characterization using a human tumor cell line panel representing different forms of drug resistance. Br J Cancer 74: 888-96, 1996
Fridborg H et al. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumor cells ex vivo and in the clinic. Eur J Cancer 35:4244-32, 1999 Nygren P & Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J Internal Med 253: 46-75, 2003 Berndtsson M et al. Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system. Int J Cancer 124: 1463-9, 2009 Gullbo J et al. Phenotype-based drug screening in primary ovarian carcinoma cultures identifies iron depletion as a promising strategy for cancer treatment. Biochem Pharmacol 82: 139?47, 2011 |
 |
 |
 |